Controlling stereoselectivity by enzymatic and chemical means to access enantiomerically pure (1
S,3
R)-1-benzyl-2,3-dimethyl-1,2,3,4-tetrahydroisoquinoline derivatives.
ACTA ACUST UNITED AC 2013;
24:744-749. [PMID:
24503964 PMCID:
PMC3912595 DOI:
10.1016/j.tetasy.2013.05.003]
[Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2013] [Accepted: 05/08/2013] [Indexed: 11/22/2022]
Abstract
A chemoenzymatic strategy for the synthesis of enantiomerically
pure novel alkaloids
(1S,3R)-1-benzyl-2,3-dimethyl-1,2,3,4-tetrahydroisoquinolines
is presented. The key steps are the biocatalytic stereoselective reductive amination of
substituted 1-phenylpropan-2-one derivatives to yield chiral amines employing microbial
ω-transaminases, and the diastereoselective reduction of a Bischler–Napieralski imine
intermediate by catalytic hydrogenation in the presence of palladium on charcoal, leading
exclusively to the desired cis-isomer.
Collapse